文献速递淋巴瘤

R-CHOP剂量强度对弥漫大B细胞淋巴瘤生存结局影响的系统综述

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review.
PubMed 文献 · Blood Adv · 2021-01-01

该系统综述依据PRISMA-P指南,检索MEDLINE、EMBASE和Cochrane CENTRAL,纳入13项研究共5188例接受R-CHOP或类似方案治疗的DLBCL患者,评估剂量强度(DI)对生存结局的影响。多数研究及较高质量的大型研究显示,降低DI与更差的生存相关;但在≥80岁亚组中,降低DI对生存的影响不一致。数据支持对<80岁的老年及适合患者使用全剂量R-CHOP,而对≥80岁患者减量R-CHOP似乎不损害生存。

要点

  • 降低R-CHOP剂量强度与DLBCL患者更差的生存结局相关。
  • 在≥80岁患者中,减量R-CHOP似乎不损害生存。
  • 数据支持对<80岁老年及适合患者使用全剂量R-CHOP。

核心结论

  • 多数研究及较高质量的大型研究显示,降低R-CHOP剂量强度与DLBCL更差的生存结局相关。
  • 在≥80岁亚组中,降低剂量强度对生存的影响不一致,减量R-CHOP似乎不损害生存。
  • 数据支持对<80岁的老年及适合患者使用全剂量R-CHOP,但对≥80岁患者并非如此。

研究设计与样本

  • 系统综述,遵循PRISMA-P指南,检索MEDLINE、EMBASE和Cochrane CENTRAL。
  • 共筛选380条记录,最终纳入13项研究,共5188例患者。

主要发现

  • 在9项报告粗生存分析的研究中,7项显示较低剂量强度(计划或相对)与更差生存相关。
  • 10项研究进行了以剂量强度为协变量的多变量分析,其中6项显示关联(P < .05),4项未显示。
  • 多数研究及较高质量的大型研究显示,降低剂量强度与更差结局相关。
  • 在≥80岁亚组中,降低剂量强度对生存的影响不一致。

关键数值与推荐

  • 剂量强度通常计算为指定药物累计实际剂量与累计计划剂量的比值乘以时间校正因子。
  • 多变量分析中6项研究显示剂量强度与生存关联的P < .05。

临床怎么用

  • 对<80岁的老年及适合DLBCL患者,支持使用全剂量R-CHOP。
  • 对≥80岁患者,减量R-CHOP似乎不损害生存,可考虑减量。
  • 仍需开展针对剂量强度的随机对照试验。

局限性

  • 纳入研究多为回顾性,剂量强度计算方法不一。
  • 多变量分析结果不一致,部分研究未显示关联。
  • ≥80岁亚组数据有限,结论不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The dilemma of whether to treat elderly patients with diffuse large B-cell lymphoma (DLBCL) with a full or reduced dose intensity (DI) of R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone+rituximab) is often faced by clinicians. We conducted a systematic review assessing the impact of R-CHOP DI on DLBCL survival outcomes, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols (PRISMA-P) guidelines. We searched MEDLINE, EMBASE, and Cochrane CENTRAL for studies with ≥100 patients treated with R-CHOP/R-CHOP-like therapies published from January 2002 through November 2020. Studies were included if they reported the impact of R-CHOP DI on survival outcomes. We screened records, extracted data, and reviewed all the studies for quality and statistical appraisal. Of 380 screened records, 13 studies including 5188 patients were reviewed. DI was often calculated as the ratio of the cumulative delivered dose of prespecified drug(s) to the cumulative planned dose multiplied by a time-correction factor. Lower DI (intended or relative) was associated with inferior survival in 7 of 9 studies reporting crude survival analyses. Multivariable analysis using DI as a covariate was performed in 10 studies. Six showed an association (P < .05) with adjustment for other covariates, and 4 did not. Most studies and those larger studies of higher quality showed poorer outcomes associated with reduced DI. In subgroups aged ≥80 years, survival was not consistently affected by reduced DI. DI-specific randomized trials are warranted, but these data support full-dose R-CHOP in elderly and fit patients aged <80 years with DLBCL, but not in those aged ≥80 years, where dose-reduced R-CHOP does not appear to compromise survival.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bataillard EJ, Cheah CY, Maurer MJ, et al. Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Adv. 2021. PMID: 33961018. doi:10.1182/bloodadvances.2021004665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。